Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:

EARNINGS HIGHLIGHTS

Q4 2017 Y/Y Blended Earnings Growth Estimates:

Story continues below advertisement

  • TSX Composite (.GSPTSE) = 20.2 per cent
  • Ex-Energy = 14.5 per cent
  • Valeant Pharmaceuticals International Inc. (VRX-TO) = -27.7 per cent
  • Healthcare Ex-VRX = 16.4 per cent
  • TSX Composite Ex-VRX = 21.0 per cent

Q4 2017 Performance vs. Earnings Expectations:

30 per cent of the TSX Composite (.GSPTSE) companies have reported Q4 2017 EPS. Of the 73 companies in the index that have reported earnings to date for Q4 2017:

  • 63.0 per cent reported above analyst expectations
  • 27.4 per cent reported below analyst expectations

REVENUE HIGHLIGHTS

Q4 2017 Y/Y Blended Revenue Growth Estimates:

  • TSX Composite (.GSPTSE) = 18.6 per cent
  • Ex-Energy = 18.2 per cent
  • Valeant Pharma (VRX-TO) = -15.7 per cent
  • Healthcare Ex-Valeant Pharma = 11.9 per cent
  • TSX Composite Ex-Valeant Pharma = 19.0 per cent

Q4 2017 Performance vs. Revenue Expectations:

Of the TSX Composite companies that have reported revenue to date for Q4 2017:

  • 57.9 per cent reported above analyst expectations
  • 9.6 per cent reported below analyst expectations

Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Story continues below advertisement

Globe app users click here for the full report

Read other research reports here.